Emily Chan

Executive Medical Director, Global Development Lead Amgen Inc.

Seminars

Tuesday 16th September 2025
Roundtable Discussion: Untangling the Regulatory Landscape Surrounding Combination Therapies to Accelerate More Innovative Treatments Towards the Patients in Need
3:45 pm
  • How to overcome the regulatory hurdles associated with combining two unapproved drugs?
  • Uncovering preclinical data and safety assessments required for combining a RAS inhibitor with another approved or unapproved drug
  • How do regulatory agencies assess and manage multi-drug interactions in clinical trials?
Tuesday 16th September 2025
Continuing Sotorasib Development by Uncovering Synergistic Combination Strategies to Treat Mutated Colorectal Cancer
4:15 pm
  • Generating data in a 4% world: Doing more with less
  • Highlighting considerations for design of pivotal phase 3 trial
  • Uncovering a robust path to achieve regulatory approval
Emily Chan, Executive Medical Director, Global Development Lead, Amgen Inc.